CPRX Catalyst Pharmaceuticals (CPRX) Insider Trading, Ownership & Congress Trades
Pharma & Biotech · Pharmaceutical preparations · CIK 0001369568
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
222
13F, latest reported quarter
Conversions, 180 days
1
Codes C/M, not in net · no price filed
Catalyst Pharmaceuticals insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
No insider purchases or sales are on record for CATALYST PHARMACEUTICALS, INC. in the period covered. Source: SEC Form 4 filings, as of 2026-10-27.
Insider
Filed
Shares
Value
Since filing
Context
- 4 earlier Form 4 trades (code P or S) here by this insider (4 sales), the last on Nov 27, 2024.
- The trade is 49.1% of the 9,106 shares held after it.
- 2 other insiders sold within 30 days.
- 222 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Harper Molly sold about $106.1K of CPRX on Dec 12, 2025; 2 other insiders sold within 30 days and 222 funds added in the latest 13F quarter.Context
- 4 earlier Form 4 trades (code P or S) here by this insider (4 sales), the last on Nov 27, 2024.
- The trade is 114.3% of the 13,579 shares held after it.
- 2 other insiders sold within 30 days.
- 222 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Harper Molly sold about $360.2K of CPRX on Dec 12, 2025; 2 other insiders sold within 30 days and 222 funds added in the latest 13F quarter.Context
- 4 earlier Form 4 trades (code P or S) here by this insider (4 sales), the last on Nov 27, 2024.
- The trade is 285.8% of the 2,360 shares held after it.
- 2 other insiders sold within 30 days.
- 222 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Harper Molly sold about $155.6K of CPRX on Dec 12, 2025; 2 other insiders sold within 30 days and 222 funds added in the latest 13F quarter.Context
- 9 earlier Form 4 trades (code P or S) here by this insider (9 sales), the last on Mar 3, 2025.
- The trade is 277.2% of the 3,962 shares held after it.
- 2 other insiders sold within 30 days.
- 222 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Commercial Officer Del Carmen Jeffrey sold about $256.2K of CPRX on Nov 26, 2025; 2 other insiders sold within 30 days and 222 funds added in the latest 13F quarter.Context
- 10 earlier Form 4 trades (code P or S) here by this insider (10 sales), the last on Sep 8, 2025.
- The trade is 17.3% of the 231,039 shares held after it.
- 2 other insiders sold within 30 days.
- 222 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Compliance/Legal Officer Elsbernd Brian sold about $908.0K of CPRX on Nov 12, 2025; 2 other insiders sold within 30 days and 222 funds added in the latest 13F quarter.137 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
no insider buys or sells on file
Congress
no House purchase disclosed in the last 12 months
Funds
222 funds bought in last quarter
more than 92% of Pharma & Biotech
Revenue
+19.8% year over year
more than 66% of Pharma & Biotech
Margin
36.4% net margin
more than 93% of Pharma & Biotech
Buybacks
$14.6M repurchased, FY to 2026-03-31
below 66% of Pharma & Biotech
Short interest
no short interest reported
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch CPRX
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
Who owns CPRX: institutional holders (13F)
13F holdings, latest reported quarter
19,158,785 sh
$602.2M
7,627,036 sh
$239.7M
5,553,921 sh
$174.6M
5,135,345 sh
$161.4M
3,634,171 sh
$114.2M
Congress trades in CPRX
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
CPRX planned insider sales (Form 144)
No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
CPRX mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
NexPoint Event Driven Fund
$2.4M position · as of 2026-06-30
3.2%
Nexpoint Merger Arbitrage Fund
$44.9M position · as of 2026-06-30
3.0%
THE ARBITRAGE FUND
$22.6M position · as of 2026-05-31
2.7%
Water Island Event-Driven Fund
$1.3M position · as of 2026-05-31
2.5%
AltShares Event-Driven ETF
$308.5K position · as of 2026-05-31
2.5%
ProShares Merger ETF
$371.3K position · as of 2026-05-31
2.3%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Clinical pipeline
5 registered trials, 1 still running (ClinicalTrials.gov).
A status change is dated here weeks before the press release.
1
Phase 2
0 active
2
Phase 3
0 active
2
Not applicable
1 active
Matched by sponsor name. Trials run under a subsidiary's
own name are not included.
Executive pay vs shareholder return · Richard J. Daly
CEO pay, headline and as actually paid, against the company's
return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2024
$7.8M
$12.9M
$3.7M
+457%
-12%
2023
$2.1M
$1.0M
$2.3M
+348%
-46%
2022
$6.9M
$17.5M
$2.7M
+396%
-31%
2021
$2.1M
$5.4M
$1.4M
+81%
-6%
2020
$1.8M
$1.5M
$1.2M
-11%
+13%
Tagged by the company under SEC Item 402(v). Returns are
cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows 222 funds added last quarter. Each figure is a federal filing, dated the day it went public.
CPRX financials
Revenue growth
+19.8%
XBRL, annual
Net margin
36.4%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$597.0M
four quarters, 2025-04-01 to 2026-03-31
Revenue, TTM CPRX
| FY Dec 2025 | $589.0M |
| FY Dec 2024 | $491.7M |
| FY Dec 2023 | $398.2M |
| FY Dec 2022 | $214.2M |
| FY Dec 2021 | $140.8M |
| Mar 2026 | $149.4M |
| Dec 2025 | $152.6M |
| Sep 2025 | $148.4M |
| Jun 2025 | $146.6M |
| Mar 2025 | $141.4M |
| Dec 2024 | $141.8M |
| Sep 2024 | $128.7M |
| Jun 2024 | $122.7M |
At each fiscal year end
Single quarter
Net margin, TTM
+37.1%
net income over revenue, 2025-04-01 to 2026-03-31
Net margin, TTM CPRX
| FY Dec 2025 | +36.4% |
| FY Dec 2024 | +33.3% |
| FY Dec 2023 | +17.9% |
| FY Dec 2022 | +38.8% |
| FY Dec 2021 | +28.0% |
| Mar 2026 | +42.7% |
| Dec 2025 | +34.5% |
| Sep 2025 | +35.6% |
| Jun 2025 | +35.6% |
| Mar 2025 | +40.1% |
| Dec 2024 | +39.4% |
| Sep 2024 | +34.1% |
| Jun 2024 | +33.2% |
At each fiscal year end
Single quarter
Free cash flow, TTM
$208.1M
operating cash flow minus capex, 2025-04-01 to 2026-03-31
Free cash flow, TTM CPRX
| FY Dec 2025 | $208.6M |
| FY Dec 2024 | $239.3M |
| FY Dec 2023 | $143.4M |
| FY Dec 2022 | n/a |
| FY Dec 2021 | $59.4M |
| Mar 2026 | $59.6M |
| Dec 2025 | $44.9M |
| Sep 2025 | $32.4M |
| Jun 2025 | $71.3M |
| Mar 2025 | $60.0M |
| Dec 2024 | $70.8M |
| Sep 2024 | $72.6M |
| Jun 2024 | $64.1M |
At each fiscal year end
Single quarter
Debt to equity
n/a
no debt line filed
Debt to equity CPRX
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
| Jun 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
n/a
no debt line filed
Cash flow to debt CPRX
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
| Jun 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
+24.5%
TTM net income over average of 2025-03-31 and 2026-03-31
Return on equity CPRX
| FY Dec 2025 | +25.5% |
| FY Dec 2024 | +29.4% |
| FY Dec 2023 | +20.7% |
| FY Dec 2022 | +32.8% |
| FY Dec 2021 | +21.0% |
| Mar 2026 | +24.5% |
| Dec 2025 | +25.5% |
| Sep 2025 | +27.5% |
| Jun 2025 | +28.5% |
| Mar 2025 | +29.1% |
| Dec 2024 | +29.4% |
| Sep 2024 | +28.3% |
| Jun 2024 | +13.9% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
+21.5%
TTM net income over average of 2025-03-31 and 2026-03-31
Return on assets CPRX
| FY Dec 2025 | +21.9% |
| FY Dec 2024 | +24.8% |
| FY Dec 2023 | +16.9% |
| FY Dec 2022 | +27.1% |
| FY Dec 2021 | +18.4% |
| Mar 2026 | +21.5% |
| Dec 2025 | +21.9% |
| Sep 2025 | +23.9% |
| Jun 2025 | +24.9% |
| Mar 2025 | +25.4% |
| Dec 2024 | +24.8% |
| Sep 2024 | +24.1% |
| Jun 2024 | +11.8% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
no debt line filed
Return on invested capital CPRX
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
| Jun 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
+29.5%
operating income (EBIT proxy) over average of 2025-03-31 and 2026-03-31 minus current liabilities
Return on capital employed CPRX
| FY Dec 2025 | +30.6% |
| FY Dec 2024 | +34.7% |
| FY Dec 2023 | +24.4% |
| FY Dec 2022 | +38.5% |
| FY Dec 2021 | +27.5% |
| Mar 2026 | +29.5% |
| Dec 2025 | +30.6% |
| Sep 2025 | +32.6% |
| Jun 2025 | +33.1% |
| Mar 2025 | +33.9% |
| Dec 2024 | +34.7% |
| Sep 2024 | +34.0% |
| Jun 2024 | +17.1% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
18.10x
close 2026-07-21 over four quarters of diluted EPS, 2025-04-01 to 2026-03-31
P/E, trailing CPRX
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
| Jun 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
n/a
no debt line filed
Enterprise value CPRX
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
| Jun 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
+5.4%
TTM free cash flow over market value at close 2026-07-21
FCF yield CPRX
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
| Jun 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
1.67x
P/E over trailing EPS growth of 11%: four quarters to 2026-03-31 against the four to 2025-03-31
PEG, trailing CPRX
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
| Jun 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-07-21. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $589.0M | $491.7M | $398.2M | $214.2M |
| Operating income | $257.8M | $195.1M | $86.8M | $101.8M |
| Net income | $214.3M | $163.9M | $71.4M | $83.1M |
| EPS (diluted) | 1.68 | 1.31 | 0.63 | 0.75 |
| Operating cash flow | $208.7M | $239.8M | $143.6M | $116.0M |
| Cash | $709.2M | $517.6M | $137.6M | $298.4M |
| Buybacks | $25.3M | $0 | $0 | $6.9M |
SEC XBRL, fiscal years, as known on 2026-10-27
CPRX Stock Sonar score 4/7 axes
Find similar shapesCompareCPRX ranks highest on profitability (93rd percentile) and growth (66th), and lowest on risk and compliance (14th), among Pharma & Biotech peers.
4 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
